Clinical Trial

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

Study acronym: ITHRAN
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-11.
Status change: Not Yet Recruiting → Recruiting 2025-11-16
Trial Details
NCT Number NCT07180160
Lead Sponsor Wenjin Yin
Conditions Advanced Breast Cancer
Enrollment 123 participants
Start Date 2025-09-25
Primary Completion 2027-09 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2025-11-18